Stem Cells As Regeneration Treatment For Heart Attacks (CYTX)

May 28, 2009 · Filed Under stem cells 

Cytori Therapeutics, Inc. (NASDAQ: CYTX) is trading higher on the publication of the first pre-clinical study to demonstrate adipose-derived stem and regenerative cells showing significantly improved cardiac function after a heart attack.

As a reminder, there has been more than steady talk of mergers in the stem cell sector.

This pre-clinical data cardiac cell therapy study was reported online ahead of print in the International Journal of Cardiology. The APOLLO study is, according to Cytori, the first clinical trial to investigate uncultured adipose-derived stem and regenerative cells in heart attacks in human patients.

Enrollment was recently completed in APOLLO as a double blind and placebo controlled safety and feasibility trial. The expected data looks to be coming in early 2010.

Cytori sponsored the APOLLO study and it has incorporated its Celution System to automate the processing of the patients’ cells at the point of care.

So far shares are responding positively to the news.  Cytori’s stock is up almost 8% at $3.31, and its 52-week trading range is $1.42 to $8.56.

JON C. OGG
May 28, 2009

Tags:

Comments

Comments are closed.

    Subscribe to BioHealth Investor BioHealth Investor RSS Feed